Ligand Pharmaceuticals Inc (LGND)
115.45
-6.63
(-5.43%)
USD |
NASDAQ |
Nov 14, 16:00
110.55
-4.90
(-4.24%)
After-Hours: 06:22
Ligand Pharmaceuticals Free Cash Flow (Quarterly): 22.29M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 22.29M |
| June 30, 2024 | 11.18M |
| March 31, 2024 | 16.18M |
| December 31, 2023 | -42.68M |
| September 30, 2023 | 7.159M |
| June 30, 2023 | -0.285M |
| March 31, 2023 | 31.53M |
| December 31, 2022 | 52.30M |
| September 30, 2022 | 15.20M |
| June 30, 2022 | 5.29M |
| March 31, 2022 | 47.14M |
| December 31, 2021 | 25.45M |
| September 30, 2021 | 18.25M |
| June 30, 2021 | 18.99M |
| March 31, 2021 | 7.35M |
| December 31, 2020 | -1.093M |
| September 30, 2020 | 10.71M |
| June 30, 2020 | 23.59M |
| March 31, 2020 | 16.92M |
| December 31, 2019 | -7.339M |
| September 30, 2019 | -6.197M |
| June 30, 2019 | -61.06M |
| March 31, 2019 | 45.26M |
| December 31, 2018 | 32.57M |
| September 30, 2018 | 27.08M |
| Date | Value |
|---|---|
| June 30, 2018 | 73.64M |
| March 31, 2018 | 60.76M |
| December 31, 2017 | 31.31M |
| September 30, 2017 | 27.65M |
| June 30, 2017 | 10.39M |
| March 31, 2017 | 19.22M |
| December 31, 2016 | 25.71M |
| September 30, 2016 | 16.34M |
| June 30, 2016 | -8.292M |
| March 31, 2016 | 7.43M |
| December 31, 2015 | 11.80M |
| September 30, 2015 | 9.159M |
| June 30, 2015 | 5.583M |
| March 31, 2015 | 4.322M |
| December 31, 2014 | 7.683M |
| September 30, 2014 | 3.467M |
| June 30, 2014 | 3.964M |
| March 31, 2014 | 0.953M |
| December 31, 2013 | 11.03M |
| September 30, 2013 | -0.564M |
| June 30, 2013 | 3.245M |
| March 31, 2013 | 2.041M |
| December 31, 2012 | 2.21M |
| September 30, 2012 | -4.782M |
| June 30, 2012 | -0.974M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-42.68M
Minimum
Dec 2023
52.30M
Maximum
Dec 2022
13.91M
Average
15.69M
Median
Free Cash Flow (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | 1.049B |
| Agios Pharmaceuticals Inc | -84.64M |
| ADMA Biologics Inc | 23.93M |
| Pieris Pharmaceuticals Inc | -1.48M |
| AnaptysBio Inc | -10.12M |